OSTX
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- OS Therapies completed its FDA Type C statistical methods meeting and provided an update on global regulatory coordination for OST-HER2 under Project OrbisSep 21, 2026
- OS Therapies reached further alignment with the FDA and accepted an MHRA invitation to Project Orbis for its OST-HER2 metastatic osteosarcoma programSep 17, 2026
- OS Therapies announced full alignment with the UK MHRA and EU EMA on filing a conditional marketing authorization applicationSep 15, 2026
- OS Therapies received FDA approval for a Type C statistical methods meeting to review 2.5-year overall survival data for OST-HER2 in preventing or delaying recurrence of fully resected pulmonary metastatic osteosarcomaAug 13, 2026
- OS Therapies submitted a new FDA meeting request to review biomarker data under the BEST programJul 9, 2026